Statins Can Cause Myasthenia Gravis: Fact or Fiction?

Virgo, Jonathan; Wong, Sui; Rantell, Khadija; Plant, Gordon T.

doi:10.1136/jnnp-2013-306573.211

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myasthenia gravis is an autoimmune disease in which autoantibodies block or destroy the nicotinic acetylcholine receptors on the sarcolemma, thereby leading to weakness of voluntary muscles of the eye, face, throat, and limbs [99]. The incidence is estimated to vary between 0.3 and 2.8 cases/per 100,000 persons [100].…”

Section: Statins In Myasthenia Gravismentioning

confidence: 99%

“…Starting in 2000, a series of case reports drew attention to the possibility of statininduced myasthenic syndrome [99,104] or worsening of preexisting MG after statin exposure [105]. Patients with statin-induced MG were either sero-positive or-negative for acetylcholine receptor antibodies [106], but symptoms improved after statin cessation and/or immunosuppressive therapy [107] and, in some cases, reemerged after statin rechallenge [105].…”

Section: Statins In Myasthenia Gravismentioning

confidence: 99%

See 1 more Smart Citation

Cholesterol Management in Neurology: Time for Revised Strategies?

Andronie‐Cioara

Jurcău

et al. 2022

JPM

View full text Add to dashboard Cite

Statin therapy has been extensively evaluated and shown to reduce the incidence of new or recurrent vascular events, ischemic stroke included. As a consequence, each published guideline pushes for lower low-density cholesterol levels in the population at large, recommending increased statin doses and/or adding new cholesterol-lowering molecules. Neurologists find it sometimes difficult to apply these guidelines, having to confront situations such as (1) ischemic strokes, mainly cardioembolic ones, in patients with already low LDL-cholesterol levels; (2) myasthenic patients, whose lifespan has been extended by available treatment, and whose age and cholesterol levels put them at risk for ischemic stroke; (3) patients with myotonic dystrophy, whose disease often associates diabetes mellitus and heart conduction defects, and in whom blood cholesterol management is also not settled. As such, further trials are needed to address these issues.

show abstract

Section: Statins In Myasthenia Gravismentioning

confidence: 99%